NeuroMetrix currently holds 382.08
K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. The entity has a current ratio of 12.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist NeuroMetrix until it has trouble settling it off, either with new capital or with free cash flow. So, NeuroMetrix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NeuroMetrix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NeuroMetrix to invest in growth at high rates of return. When we think about NeuroMetrix's use of debt, we should always consider it together with cash and equity.
NeuroMetrix financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of NeuroMetrix, including all of NeuroMetrix's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of NeuroMetrix assets, the company is considered highly leveraged. Understanding the
composition and structure of overall NeuroMetrix debt and outstanding corporate bonds gives a good idea of
how risky the capital structure of a business is and if it is worth investing in it. Please read more on our
technical analysis page.
Understanding NeuroMetrix Total Debt
NeuroMetrix liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. NeuroMetrix has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on NeuroMetrix balance sheet include debt obligations and money owed to different NeuroMetrix vendors, workers, and loan providers. Below is the chart of NeuroMetrix main long-term debt accounts currently reported on its balance sheet.
You can use NeuroMetrix
financial leverage analysis tool to get a better grip on understanding its financial position
How important is NeuroMetrix's Liquidity
NeuroMetrix
financial leverage refers to using borrowed capital as a funding source to finance NeuroMetrix ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NeuroMetrix financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to NeuroMetrix's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of NeuroMetrix's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between NeuroMetrix's total debt and its cash.
A Deeper Perspective
The modest gains experienced by current holders of NeuroMetrix may encourage insiders to take a closer look at the firm as it is trading at a share price of
1.69 on
8,371 in trading volume. The company management teams have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in
January. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.29. The above-average risk is mostly attributed to
market volatility and speculations regarding some of the upcoming earning calls from NeuroMetrix partners.
Liabilities Breakdown
| Total Liabilities | 1.54 Million |
| Current Liabilities | 1.61 Million |
| Long-Term Liabilities | 283,302 |
Will NeuroMetrix price decline impact its balance sheet?
The mean deviation is down to 2.66 as of today. NeuroMetrix shows above-average downside volatility for the selected time horizon. We advise investors to inspect NeuroMetrix further and ensure that all market timing and asset allocation strategies are consistent with the estimation of NeuroMetrix future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure NeuroMetrix's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact NeuroMetrix's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Takeaway on NeuroMetrix Investment
Although other entities under the medical devices industry are still a bit expensive, NeuroMetrix may offer a potential longer-term growth to insiders. While some insiders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NeuroMetrix.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of NeuroMetrix. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com